Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein bicaudal D homolog 2 (BICD2) is a conserved coiled-coil cargo adaptor protein involved in intracellular transport. It functions primarily by binding and activating the dynein-dynactin motor complex, facilitating minus-end-directed transport along microtubules. BICD2 couples dynein to a variety of cargos—including Golgi-derived vesicles and synaptic vesicles—by interacting via its C-terminal domain with cargo proteins such as the GTPase Rab6. In neurons, BICD2 is crucial for the proper transport of synaptic vesicles. Mutations in BICD2 are associated with autosomal dominant spinal muscular atrophy with lower extremity predominance (SMA-LED), manifesting as lower limb muscle weakness and atrophy[4][1][2][3]. BICD2 is not a typical pharmacological target such as an enzyme or receptor, and no known drugs currently act directly on this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein bicaudal D homolog 2 (BICD2).